Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Potentially Curable Pancreatic Cancer Guideline Updated

J Clin Oncol; ePub 2017 Apr 11; Khorana, et al

Publish date:: April 18, 2017

The American Society of Clinical Oncology has updated its 2016 guideline on potentially curable pancreatic cancer in light of results of a randomized phase 3 study. Among the revisions:

Offer patients with resected pancreatic cancer who did not receive preoperative therapy 6 months of adjuvant chemotherapy in the absence of medical or surgical contraindications.
Offer the doublet regimen of gemcitabine and capecitabine if there are no toxicity/tolerance concerns; alternatively, offer monotherapy with gemcitabine or fluorouracil plus folinic acid.
Initiate adjuvant treatment within 8 weeks of surgical resection, assuming complete recovery.

Citation:

Khorana A, Mangu P, Berlin J, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline update. [Published online ahead of print April 11, 2017]. J Clin Oncol. doi:10.1200/JCO.2017.72.4948.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Upper GI bleeds in COVID-19 not related to increased mortality,

Cryoballoon, cryospray found equivalent for eradicating Barret’s esophagus,